August 2026 clinical trial highlights
Research study participants are essential in the quest for new treatments and a cure for pulmonary fibrosis (PF).
Each month, we'll highlight a few of the many trials enrolling volunteers. All past issues are available on the PFF Clinical Trials Blog. To view more trials for various forms of interstitial lung disease (ILD), visit the 🔍 PFF Clinical Trial Finder.
Seeking participants with idiopathic pulmonary fibrosis (IPF)-related chronic cough
OCEAN-1
- Study ID: NCT07671911
- Trial Phase: Phase 3
- Intervention: Oral drug
- Sponsor: Trevi Therapeutics
- Study Contact: Paula Buckley (203.304.2499; Paula.Buckley@trevitherapeutics.com)
Seeking participants with PF
DROP-FPF
- Study ID: NCT07201922
- Trial Phase: Phase 3
- Intervention: Oral drug
- Sponsor: Boehringer Ingelheim
- Study Contact: Boehringer Ingelheim (800.243.0127; clintriage.rdg@boehringeringelheim.com)
Seeking lung transplant recipients
CLAD
- Study ID: NCT06476132
- Trial Phase: Phase 2
- Intervention: Oral drug
- Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Seeking participants with rheumatoid arthritis associated with interstitial lung disease (RA-ILD)
Defining the Molecular and Radiologic Phenotype of Progressive RA-ILD (MOUNTAIN)
- Study ID: NCT06397677
- Intervention: Blood or biological sample collection
- Sponsor: University of Colorado, Denver
- Sponsor Contact: Olivia Brohl (303.724.0640; olivia.brohl@cuanschutz.edu); Joyce S. Lee (303.724.6109; joyce.lee@cuanschutz.edu)
Putting a face to the science: living with scleroderma-associated interstitial lung disease (SSc-ILD)
After Donna was diagnosed with SSc-ILD, her physician suggested enrolling inan upcoming clinical trial. Driven by trust in her physician and a commitment toadvancing science, Donna decided to participate in a clinical trial after carefullyweighing its pros and cons with her husband.
Donna dedicated five and a half years to the initial clinical trial and its follow-up study. She credits the study medication with slowing down her lung fibrosis, which further enabled her to watch her two sons growing up, travel, enjoy bird watching, and spend dinners with friends. Furthermore, Donna’s clinical trial experiences left her with more knowledge to make decisions for her own healthcare, a stronger bond with her medical team, and the confidence to engage directly with researchers and health leaders.
To learn more about SSc-ILD, view the Scleroderma-Associated Interstitial Lung Disease Fact Sheet. If you would like to share your journey like Donna, complete the "My research study story" form. This initiative aims to highlight unique perspectives from the PF and ILD community.
 |
Positive results from Phase 1b IPF study
In July 2026, MannKind announced its phase 1b INFLO-1 study met its primary endpoint, which evaluated the use of nintedanib dry powder inhalation (DPI) (MNKD-201) in IPF. A primary endpoint is a key measurement researchers use to determine the efficacy of a medication or intervention. The study demonstrated that individuals with IPF who took nintedanib DPI had no serious adverse events. Reported cough events were predominantly mild, brief, and resolved.
Nintedanib DPI carries the medication deep into the airways when it’s inhaled, which is thought to permit the drug to directly reach and target the lung damage and scarring areas.
Watch the CTI Series recordings
If you have any questions or comments about this newsletter, please email partnerships@